DOCSLIB.ORG

Lysergic Acid Diethylamide As a Multi-Target Therapeutic for Alzheimer’S Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lysergic Acid Diethylamide As a Multi-Target Therapeutic for Alzheimer’S Disease WHITE PAPER Lysergic Acid Diethylamide as a Multi-Target Therapeutic for Alzheimer’s Disease By Shlomi Raz, Eleusis Therapeutics Ltd September 2020 Additional contributors: Nichols C.D. , Maillet E. L. , Grantham C. , Family N. new approachesnew to diseaseapproaches modification to disease 7, 8modification. Multi-targeted 7, 8. Multidrugs- targeted(MTDs) with drugs established (MTDs) with safety established profiles safety profiles could empiricallycould engag empiricallye identified engag therapeutice identified targets therapeutic 9. targets 9. We propose theW hypothesise propose thatthe hypothesis low-dose l ysergicthat low acid-dose diethylamide lysergic acid (LSD diethylamide) represents (LSD a promising) represents a promising INTRODUCTIONdisease modifyingdisease therapeutic modifying for therapeuticAD. LSD is a forclassic AD. psychedelic LSD is a classic drug psychedelic and is one drugof the and most is one well of-studied the most well-studied 10, 11 10, 11 Alzheimer’s Disease psychoactive(AD) is adrugs psychoactiveheterogenous in the history drugs pharmacology ofin modernthe history pharmacology10,11 of and modern shares pharmacology structural. It shares similarity structural. It sharesto similarity structural to 5- HTsimilarity to 5-HT neurodegenerative disease expected to afflict nearly 5-HT (FIGURE 1). 15 million people over 65(FIGURE in the US 1). by 2050(FIGURE (Alzheimer’s 1). Association, 2020). Mild cognitive impairment (MCI) is a prodromal state of AD, associated with amnesic cognitive dysfunction distinct from normal aging. The progression of MCI to AD features multiple dysregulated physiological cascades that characteristically feature the accumulation of abnormally folded amyloid-β (Aβ) and tau proteins in amyloid plaques and neurofibrillary tangle deposits1. The multifactorial nature of early-stage AD suggests multiple pathophysiological processes, including neuroinfammmation2, synaptic degeneration3, neuropsychiatric/neurendocrine dysfunction4,5 and brain insulin resistance6, all of which are potential targets for therapeutic intervention. Targeted immunotherapies capable of disease modification by reducing βA and tau burden have failed to influence AD progression in late-stage clinical trials, and the only FDA-approved drug therapies are symptomatic in natureFIGURE with marginal1. illustrationsFIGURE and transient of1. 5illustrations-HT and LSD, of highlighting5-HT and LSD, their highlighting similarities their in structure similarities in colorin structure (Adapted in colorfrom (Adapted from clinical efficacy, highlighting the urgent need for new FIGURE 1. illustrations of 5-HT and LSD, highlighting their approaches to disease modification7,8. Multi-targeted similarities in structure in color (Adapted from Nichols DE. Nichols DE. Serotonin,Nichols DE. and Serotonin, theSerotonin, Past and and and Future the Past Past ofand andLSD Future Future. MAPS of LSD. of MAPSBulletin LSD Bulletin. MAPS Spring Bulletin 2013). Spring 2013). drugs (MTDs) with established safety profiles could Spring 2013). empirically engage identified therapeutic targets9. This article sets out the evidence and arguments for We propose the hypothesis that low-dose lysergic why the pharmacology of LSD, when administered acid diethylamide (LSD) represents a promising This article setsThis out article the atevidence setssub-psychoactive out andthe argumentsevidence doses, and for makes argumentswhy itthe an pharmacology forappealing why the pharmacologyof LSD, when of LSD, when disease modifying therapeutic for AD. LSD is a disease-modifying therapeutic candidate for AD, and classic psychedelic drug and is one of the most well- provides background for the design and conduct of studied psychoactive drugsadministered in the history atadministered sub -ofpsychoactive modern at subfurther doses,-psychoactive studiesmakes it todoses, an evaluate appealing makes its efficacy.itdisease an appealing-modifying disease therapeutic-modifying candidate therapeutic candidate for AD, and providesfor AD, background and provides for background the design and for theconduct design of andfurther conduct studies of furtherto evaluate studies its efficacy.to evaluate its efficacy. SEROTONINERGIC SYSTEM IN AGEING AND AD 5-HT is a monoamine neurotransmitterSEROTONINERGICSEROTONINERGIC and hormone SYSTEM CNS IN by AGEINGSYSTEM 5-HT could ANDIN result AGEING AD in opposing AND effects.AD Instead, that exerts a direct modulatory influence on nearly selective activation of only relevant 5-HT receptors all the pathological, physiological and behavioral may maximize therapeutic value of 5-HT receptor changes observed in AD12,13. Preclinical5-HT is a monoamine and 5clinical-HT is neurotransmittera monoaminetargeted therapeutics. neurotransmitter and hormone that and exertshormone a direct that exertsmodulatory a direct influence modulatory influence data suggest that modulating 5-HT receptors may be a useful therapeutic strategy for AD, eg. Selective LSD binds to a subset of serotonin (5-HT), dopamine 12, 13 12, 13 serotonin reuptake oninhibitors nearly all (SSRIs)theon pathological nearly preserve all the physiological pathologicaland other and biogenicphysiological behavior amineal andchanges receptors behavior observed alwith changes differentin AD observed . Preclinical in AD and. Preclinical and cognition, suppress microglial activation, and lower affinities. The biological effect of LSD is related to brain Aβ levels in AD clinicalanimal datamodels suggestclinical14-17, while that data long-modulating suggestits receptorthat 5-HT modulating receptors binding 5andmay-HT occupancy,receptorsbe a useful may which therapeutic be ina turnuseful strategy is therapeutic for AD, strategy eg. for AD, eg. term SSRI use (> 4 years) delays the conversion of governed by the concentration of LSD to which the MCI to AD in MCI patients18. Because SSRIs do not receptor is exposed. At low, sub-psychoactive doses, demonstrate a robust disease modifying effect LSD selectively occupies several of the 5-HT receptor in depressed MCI patients, it is possible that the subtypes (see heatmap in TABLE 1). indiscriminate activation of all 5-HT receptors in the LSD for Alzheimer's (Review) Copyright © 2020 Eleusis Therapeutics Ltd 1 SEROTONINERGIC SYSTEM IN exceptionAGEING of the 5-HT AND3 and 5-HT 4 ADreceptors, (CONT’D) and is quantitatively different in its activation profile, depending on dose 11. We have recently demonstrated the safety and tolerability of chronic low dose LSD NE NE DA DA DA DA Hist 5-HT 5-HT 5-HT 5-HT 5-HT 5-HT 5-HT 5-HT 5-HT (i.e. doses up to 20 μg) in healthy elderly volunteers19. In this study, no physiological or behavioral effects Receptor Target B1 B2 2 3 4 5 1 1A 1D 1E 2A 2B 2C 5A 6 7 Apparent significantly differed from placebo and pharmacokinetic evaluation suggest that plasma levels are in the 6.9 6.1 6.9 7.6 7.3 6.5 5.8 8.9 8.4 7.0 8.4 7.5 7.8 8.1 8.2 8.2 affinity (-pKi) low nanomolar concentration range consistent with moderate occupancy and a more subtle engagement LSD Poly-pharmacological Profile (receptor sites occupancy in %) concentration profile at 5-HT receptors in the brain devoid of excessive pharmacology hallmarks (FIGURE 2, Table 1 see 10 nM 7 1 8 27 15 3 1 90 72 10 69 25 38 53 60 61 1nM row of polypharmacological profile). We propose that the functional selectivity and potency of LSD 1 nM 1 0 1 4 2 0 0 47 20 1 18 3 6 10 13 13 20 at 5-HT2A receptors, which underlies its neuropsychological psychedelic properties at higher doses , 0.1 nM 0 0 0 0 0 0 0 8 3 0 2 0 1 1 1 2 together with its selective modulation of certain other 5-HT and dopamine receptors, represents a novel TABLE 1. Estimated polypharmacological profile of LSD shows the fraction of each receptor type that is saturated or bound by LSD Occupancy at different theoretical concentrations of LSD was estimatedpolypharmacological by the Hill-Langmuir-based strategy equation for the assumingdisease modification a Hill coefficient of AD. of 1 and using the average experimental Ki values for apparent affinity at human receptors in cellular models. Source of Ki information: CHEMBL (accessed April 2020) NE, norepinephrine; DA, dopamine; Hist, histamine, 5-HT, serotonin LSD is qualitatively distinct from 5-HT in that it differentially modulates 5-HT receptors, possessing 20 µg oral LSD partial agonist, agonist and antagonist properties at the various 5-HT receptor subtypes with the exception of the 5-HT3 and 5-HT4 receptors, and is quantitatively different in its activation profile, depending on dose11. We have recently demonstrated the safety and tolerability of chronic low dose LSD (i.e. doses up to 20 μg) in healthy elderly volunteers19. In this study, no physiological or behavioral effects significantly differed from placebo and pharmacokinetic evaluation suggest that plasma levels are in Plasmadrugconcentration a nanomolar concentration range consistent with moderate occupancy and a more subtle engagement profile at 5-HT receptors in the brain, devoid of excessive pharmacology hallmarks (FIGURE 2, Table 1 see 1 nM row of polypharmacological profile). We propose that the functional selectivity and FIGURE 2. Plasma drug levels of LSD in humans after potency of LSD at 5-HT2A receptors, which underlies administration of a non-psychedelic “microdose” of LSD. its neuropsychological psychedelic properties at The average CMax in plasma was 0.44 ng/ml, which is equivalent higher doses20, together with its selective modulation to 1.5 nanomolar (nM) concentrations. The dotted line represents
Load more

Recommended publications
  • TABLE 1 Studies of Antagonist Activity in Constitutively Active
    TABLE 1 Studies of antagonist activity in constitutively active receptors systems shown to demonstrate inverse agonism for at least one ligand Targets are natural Gs and constitutively active mutants (CAM) of GPCRs. Of 380 antagonists, 85% of the ligands demonstrate inverse agonism. Receptor Neutral Antagonist Inverse Agonist Reference Human β2-adrenergic Dichloroisoproterenol, pindolol, labetolol, timolol, Chidiac et al., 1996; Azzi et alprenolol, propranolol, ICI 118,551, cyanopindolol al., 2001 Turkey erythrocyte β-adrenergic Propranolol, pindolol Gotze et al., 1994 Human β2-adrenergic (CAM) Propranolol Betaxolol, ICI 118,551, sotalol, timolol Samama et al., 1994; Stevens and Milligan, 1998 Human/guinea pig β1-adrenergic Atenolol, propranolol Mewes et al., 1993 Human β1-adrenergic Carvedilol CGP20712A, metoprolol, bisoprolol Engelhardt et al., 2001 Rat α2D-adrenergic Rauwolscine, yohimbine, WB 4101, idazoxan, Tian et al., 1994 phentolamine, Human α2A-adrenergic Napthazoline, Rauwolscine, idazoxan, altipamezole, levomedetomidine, Jansson et al., 1998; Pauwels MPV-2088 (–)RX811059, RX 831003 et al., 2002 Human α2C-adrenergic RX821002, yohimbine Cayla et al., 1999 Human α2D-adrenergic Prazosin McCune et al., 2000 Rat α2-adrenoceptor MK912 RX821002 Murrin et al., 2000 Porcine α2A adrenoceptor (CAM- Idazoxan Rauwolscine, yohimbine, RX821002, MK912, Wade et al., 2001 T373K) phentolamine Human α2A-adrenoceptor (CAM) Dexefaroxan, (+)RX811059, (–)RX811059, RS15385, yohimbine, Pauwels et al., 2000 atipamezole fluparoxan, WB 4101 Hamster α1B-adrenergic
    [Show full text]
  • Annual Report
    Zentralinstitut für Seelische Gesundheit Landesstiftung des öffentlichen Rechts 2017 2019 ANNUAL REPORT 2017 2019 ANNUAL REPORT EXECUTIVE BOARD RESEARCH REPORT BY THE EXECUTIVE BOARD, DEPARTMENTS, INSTITUTES DEVELOPMENT FIGURES AND RESEARCH GROUPS Report by the Executive Board 6 The Future of Therapy Research 42 Development Figures 8 Department of Neuropeptide Research 46 in Psychiatry Department of Molecular Neuroimaging 47 Department of Public Mental Health 48 Hector Institute for Translational 50 Brain Research RG Developmental Brain Pathologies 51 Department of Biostatistics 52 PATIENT CARE Institute of Cognitive and 53 Clinical Neuroscience CLINICAL DEPARTMENTS AND INSTITUTES RG Brain Stimulation, Neuroplasticity and 54 Learning RG Psychobiology of Risk Behavior 54 Clinic of Psychiatry and Psychotherapy 12 RG Body Plasticity and Memory Processes 55 Clinic of Child and Adolescent Psychiatry and 20 RG Psychobiology of Pain 56 Psychotherapy RG Psychobiology of Emotional Learning 57 Clinic of Psychosomatic Medicine and 24 Institute for Psychopharmacology 58 Psychotherapy RG Behavioral Genetics 59 RG Translational Addiction Research 60 Clinic of Addictive Behavior and 26 RG Physiology of Neuronal Networks 61 Addiction Medicine RG Molecular Psychopharmacology 62 Adolescent Center for Disorders 29 RG Neuroanatomy 63 of Emotional Regulation RG In Silico Psychopharmacology 64 Adolescent Center for 30 Institute for Psychiatric and 65 Psychotic Disorders – SOTERIA Psychosomatic Psychotherapy RG Experimental Psychotherapy 66 Central Outpatient
    [Show full text]
  • Biased Allosteric Regulation of the Prostaglandin F2α Receptor: From
    Biased Allosteric Regulation of the Prostaglandin F2 Receptor: From Small Molecules to Large Receptor Complexes By Eugénie Goupil Department of Pharmacology and Therapeutics McGill University, Montréal, Canada November, 2012 A thesis submitted to McGill in partial fulfillment of the requirements of the degree of Doctor of philosophy Copyright ©Eugénie Goupil, 2012 ''In theory, there is no difference between theory and practice. In practice, there is.'' -Lawrence Peter ''Yogi'' Berra ii Abstract G protein-coupled receptors (GPCRs) represent the largest family of cell surface receptors, and thus some of the most important targets for drug discovery. By binding to the orthosteric site where endogenous ligands bind, agonists and antagonists differentially modulate signals sent downstream from these receptors. New evidence suggests that GPCRs possess topographically distinct or allosteric binding sites, which may differentially modulate agonist- and antagonist-mediated responses to selectively affect distinct signalling pathways coupled to the same receptor. These sites may either positively or negatively regulate receptor activity, depending on the pathway in question, and thus can act as biased ligands, leading to functional selectivity (or ligand-directed signalling). Another way of allosterically regulating GPCR signalling is through receptor oligomerization, which has recently emerged as a common mechanism for regulating receptor function. The GPCR for prostaglandin F2 FP, is implicated in many important physiological responses, such as parturition, smooth muscle cell contraction and blood pressure regulation. Therefore, evaluating the potential use of allosteric modulators of FP to fine-tune PGF2-mediated signals, as well as generating a better understanding of its putative oligomerization partners would be of significant pharmacological and clinical interest.
    [Show full text]
  • Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission
    The Journal of Neuroscience, October 14, 2015 • 35(41):14057–14069 • 14057 Neurobiology of Disease Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission Alexandra Alvarsson,1* Xiaoqun Zhang,1* Tiberiu L Stan,1 Nicoletta Schintu,1 Banafsheh Kadkhodaei,2 Mark J. Millan,3 Thomas Perlmann,2,4 and Per Svenningsson1 1Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, SE-17176 Stockholm, Sweden, 2Ludwig Institute for Cancer Research, SE-17177 Stockholm, Sweden, 3Pole of Innovation in Neuropsychiatry, Institut de Recherches Servier, Centre de Recherches de Croissy, Paris 87290, France, and 4Department of Cell and Molecular Biology, Karolinska Institutet, SE-17177 Stockholm, Sweden Parkinson’s disease (PD) is a movement disorder characterized by a progressive loss of nigrostriatal dopaminergic neurons. Restoration of dopamine transmission by L-DOPA relieves symptoms of PD but causes dyskinesia. Trace Amine-Associated Receptor 1 (TAAR1) modulates dopaminergic transmission, but its role in experimental Parkinsonism and L-DOPA responses has been neglected. Here, we report that TAAR1 knock-out (KO) mice show a reduced loss of dopaminergic markers in response to intrastriatal 6-OHDA administra- tion compared with wild-type (WT) littermates. In contrast, the TAAR1 agonist RO5166017 aggravated degeneration induced by intra- striatal6-OHDAinWTmice.Subchronic L-DOPAtreatmentofTAAR1KOmiceunilaterallylesionedwith6-OHDAinthemedialforebrain bundle resulted in more pronounced rotational behavior and dyskinesia than in their WT counterparts. The enhanced behavioral sensitization to L-DOPA in TAAR1 KO mice was paralleled by increased phosphorylation of striatal GluA1 subunits of AMPA receptors. Conversely, RO5166017 counteracted both L-DOPA-induced rotation and dyskinesia as well as AMPA receptor phosphorylation.
    [Show full text]
  • The “Rights” of Precision Drug Development for Alzheimer's Disease
    Cummings et al. Alzheimer's Research & Therapy (2019) 11:76 https://doi.org/10.1186/s13195-019-0529-5 REVIEW Open Access The “rights” of precision drug development for Alzheimer’s disease Jeffrey Cummings1*, Howard H. Feldman2 and Philip Scheltens3 Abstract There is a high rate of failure in Alzheimer’s disease (AD) drug development with 99% of trials showing no drug- placebo difference. This low rate of success delays new treatments for patients and discourages investment in AD drug development. Studies across drug development programs in multiple disorders have identified important strategies for decreasing the risk and increasing the likelihood of success in drug development programs. These experiences provide guidance for the optimization of AD drug development. The “rights” of AD drug development include the right target, right drug, right biomarker, right participant, and right trial. The right target identifies the appropriate biologic process for an AD therapeutic intervention. The right drug must have well-understood pharmacokinetic and pharmacodynamic features, ability to penetrate the blood-brain barrier, efficacy demonstrated in animals, maximum tolerated dose established in phase I, and acceptable toxicity. The right biomarkers include participant selection biomarkers, target engagement biomarkers, biomarkers supportive of disease modification, and biomarkers for side effect monitoring. The right participant hinges on the identification of the phase of AD (preclinical, prodromal, dementia). Severity of disease and drug mechanism both have a role in defining the right participant. The right trial is a well-conducted trial with appropriate clinical and biomarker outcomes collected over an appropriate period of time, powered to detect a clinically meaningful drug-placebo difference, and anticipating variability introduced by globalization.
    [Show full text]
  • Subanesthetic Doses of Ketamine Transiently Decrease Serotonin Transporter Activity: a PET Study in Conscious Monkeys
    Neuropsychopharmacology (2013) 38, 2666–2674 & 2013 American College of Neuropsychopharmacology. All rights reserved 0893-133X/13 www.neuropsychopharmacology.org Subanesthetic Doses of Ketamine Transiently Decrease Serotonin Transporter Activity: A PET Study in Conscious Monkeys 1 1 1 1 1 Shigeyuki Yamamoto , Hiroyuki Ohba , Shingo Nishiyama , Norihiro Harada , Takeharu Kakiuchi , 1 ,2 Hideo Tsukada and Edward F Domino* 1 2 Central Research Laboratory, Hamamatsu Photonics KK, Hamakita, Japan; Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA Subanesthetic doses of ketamine, an N-methyl-D-aspartic acid (NMDA) antagonist, have a rapid antidepressant effect which lasts for up to 2 weeks. However, the neurobiological mechanism regarding this effect remains unclear. In the present study, the effects of subanesthetic doses of ketamine on serotonergic systems in conscious monkey brain were investigated. Five young monkeys 11 underwent four positron emission tomography measurements with [ C]-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)benzoni- 11 trile ([ C]DASB) for the serotonin transporter (SERT), during and after intravenous infusion of vehicle or ketamine hydrochloride in a 11 dose of 0.5 or 1.5 mg/kg for 40 min, and 24 h post infusion. Global reduction of [ C]DASB binding to SERT was observed during ketamine infusion in a dose-dependent manner, but not 24 h later. The effect of ketamine on the serotonin 1A receptor (5-HT1A-R) and dopamine transporter (DAT) was also investigated in the same subjects studied with [11C]DASB. No significant changes were observed in either 5-HT -R or DAT binding after ketamine infusion. Microdialysis analysis indicated that ketamine infusion transiently increased 1A serotonin levels in the extracellular fluid of the prefrontal cortex.
    [Show full text]
  • Selective Labeling of Serotonin Receptors Byd-[3H]Lysergic Acid
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 5783-5787, December 1978 Biochemistry Selective labeling of serotonin receptors by d-[3H]lysergic acid diethylamide in calf caudate (ergots/hallucinogens/tryptamines/norepinephrine/dopamine) PATRICIA M. WHITAKER AND PHILIP SEEMAN* Department of Pharmacology, University of Toronto, Toronto, Canada M5S 1A8 Communicated by Philip Siekevltz, August 18,1978 ABSTRACT Since it was known that d-lysergic acid di- The objective in this present study was to improve the se- ethylamide (LSD) affected catecholaminergic as well as sero- lectivity of [3H]LSD for serotonin receptors, concomitantly toninergic neurons, the objective in this study was to enhance using other drugs to block a-adrenergic and dopamine receptors the selectivity of [3HJISD binding to serotonin receptors in vitro by using crude homogenates of calf caudate. In the presence of (cf. refs. 36-38). We then compared the potencies of various a combination of 50 nM each of phentolamine (adde to pre- drugs on this selective [3H]LSD binding and compared these clude the binding of [3HJLSD to a-adrenoceptors), apmo ie, data to those for the high-affinity binding of [3H]serotonin and spiperone (added to preclude the binding of [3H[LSD to (39). dopamine receptors), it was found by Scatchard analysis that the total number of 3H sites went down to 300 fmol/mg, compared to 1100 fmol/mg in the absence of the catechol- METHODS amine-blocking drugs. The IC50 values (concentrations to inhibit Preparation of Membranes. Calf brains were obtained fresh binding by 50%) for various drugs were tested on the binding of [3HLSD in the presence of 50 nM each of apomorphine (A), from the Canada Packers Hunisett plant (Toronto).
    [Show full text]
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
    [Show full text]
  • The Use of Illicit Drugs As Self-Medication in the Treatment of Cluster Headache: Results from an Italian Online Survey
    XML Template (2015) [21.4.2015–2:34pm] [1–5] //blrnas3.glyph.com/cenpro/ApplicationFiles/Journals/SAGE/3B2/CEPJ/Vol00000/150048/APPFile/SG-CEPJ150048.3d (CEP) [PREPRINTER stage] Original Article Cephalalgia 0(0) 1–5 ! International Headache Society 2015 The use of illicit drugs as self-medication Reprints and permissions: sagepub.co.uk/journalsPermissions.nav in the treatment of cluster headache: DOI: 10.1177/0333102415583145 Results from an Italian online survey cep.sagepub.com C Di Lorenzo1, G Coppola2, G Di Lorenzo3, M Bracaglia4, P Rossi5 and F Pierelli4,6 Abstract Background: Cluster headache (CH) patients often receive unsatisfactory treatment and may explore illicit substances as alternatives. We aimed to explore this use of illicit drugs for CH treatment. Methods: We invited CH patients from an Internet-based self-help group to complete a questionnaire regarding their therapeutic use of illicit substances. Results: Of the 54 respondents, 29 were classified as chronic and 39 were drug-resistant cases. Fifty patients had previously tried subcutaneous sumatriptan, 40 had tried O2, and 48 had tried at least one prophylactic treatment. All 54 patients specified that they were dissatisfied with conventional treatments. Thirty-four patients had used cannabin- oids, 13 cocaine, 8 heroin, 18 psilocybin, 12 lysergic acid amide (LSA), and 4 lysergic acid diethylamide (LSD). Discussion: Some patients with intractable CH decided to try illicit drugs concomitantly with cessation of medical care. Most of these patients found suggestions for illicit drug use on the Internet. Many patients seemed to underestimate the judicial consequences of, and had an overestimated confidence in the safety of, such illicit treatments.
    [Show full text]
  • Endogenous Metabolites in Drug Discovery: from Plants to Humans
    Endogenous Metabolites in Drug Discovery: from Plants to Humans Joaquim Olivés Farrés TESI DOCTORAL UPF / ANY 201 6 DIRECTOR DE LA TESI: Dr. Jordi Mestres CEXS Department The research in this T hesis has been carried out at the Systems Pharmacolo gy Group , within the Research Programme on Biomedical Informatics (GRIB) at the Parc de Recerca Biomèdica de Barcelona (PRBB). The research presented in this T hesis has been supported by Ministerio de Ciencia e Innovación project BIO2014 - 54404 - R and BIO2011 - 26669 . Printing funded by the Fundació IMIM’s program “Convocatòria d'ajuts 2016 per a la finalització de tesis doctorals de la Fundació IMIM.” Agraïments Voldria donar les gràcies a tanta gent que em fa por deixar - me ningú. Però per c omençar haig agrair en especial al meu director la tesi, Jordi Mestres, per donar - me la oportunitat de formar part del seu laboratori i poder desenvolupar aquí el treball que aquí es presenta. A més d’oferir l’ajuda necessària sempre que ha calgut. També haig de donar les gràcies a tots els companys del grup de Farmacologia de Sistemes que he anat coneguent durants tots aquests anys en què he estat aquí, en especial en Xavi, a qui li he preguntat mil coses, en Nikita, pels sdfs que m’ha anat llençant a CTL ink, i la Irene i la Cristina, que els seus treballs també m’ajuden a completar la tesis. I cal agrair també a la resta de companys del laboratori, l’Albert, la Viktoria, la Mari Carmen, l’Andreas, en George, l’Eric i l’Andreu; de Chemotargets, en Ricard i en David; i altres membres del GRIB, com són l’Alfons, en Miguel, en Pau, l’Oriol i la Carina.
    [Show full text]
  • La Place Des Composés Multi Target Directed Ligands Dans Le Traitement De La Maladie D’Alzheimer Katia Hamidouche
    La place des composés Multi Target Directed Ligands dans le traitement de la maladie d’Alzheimer Katia Hamidouche To cite this version: Katia Hamidouche. La place des composés Multi Target Directed Ligands dans le traitement de la maladie d’Alzheimer. Sciences pharmaceutiques. 2017. dumas-01556379 HAL Id: dumas-01556379 https://dumas.ccsd.cnrs.fr/dumas-01556379 Submitted on 5 Jul 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE DE CAEN NORMANDIE ANNEE 2017 U.F.R. DES SCIENCES PHARMACEUTIQUES THESE POUR LE DIPLOME D’ETAT DE DOCTEUR EN PHARMACIE PRESENTEE PAR Katia HAMIDOUCHE SUJET : La place des composés "Multi Target Directed Ligands" dans le traitement de la maladie d'Alzheimer SOUTENUE PUBLIQUEMENT LE : 31/03/2017 JURY : Pr. Michel Boulouard PRESIDENT DU JURY Dr. Véronique Lelong Boulouard EXAMINATEUR Dr. Joanna Bourgine EXAMINATEUR Pr. Thomas Freret Remerciements Avant tout, je tiens à dédier ce travail à mes parents , que je remercie également profondément pour leurs longs encouragements et soutien, et à qui je présente toute ma reconnaissance et gratitude pour les sacrifices qu’ils ont choisis de faire afin de nous permettre, ma sœur, mes frères et moi -même de faire ces grandes études, et sans lesquels je n’aurai jamais découvert cet univers de savoir et de science « à la Française ».
    [Show full text]
  • Ergot Alkaloids As Dopamine Agonists: Comparison in Two Rodent Models
    European Journal of Pharmacology, 37 (1976) 295-302 295 © North-Holland Publishing Company, Amsterdam - Printed in The Netherlands ERGOT ALKALOIDS AS DOPAMINE AGONISTS: COMPARISON IN TWO RODENT MODELS GILL ANLEZARK, CHRIS PYCOCK and BRIAN MELDRUM Department of Neurology, Institute of Psychiatry, Denmark Hill, London, SE5 8AF, U.K. Received 18 December 1975, revised MS received 20 February 1976, accepted 26 February 1976 G. ANLEZARK, C. PYCOCK and B. MELDRUM, Ergot alkaloids as dopamine agonists: comparison in two rodent models, European J. Pharmacol. 37 (1976) 295-302. A series of ergot alkaloids, together with the DA agonists apomorphine and piribedil, were tested for protec- tive effects against audiogenic seizures in an inbred strain of mice (DBA/2) and for induction of circling behaviour in mice with unilateral destruction of one nigrostriatal DA pathway. The order of potency against audiogenic sei- zures was apomorphine> ergocornine> bromocryptine > ergometrine> LSD> methysergide > piribedil while that observed in the rotating mouse model was apomorphine> ergometrine> ergocornine> brornocryptine > piribedil. LSD caused only weak circling behaviour even when administered in high doses (> 1 mg/kg). Methyser- gide was ineffective. Prior administration of the neuroleptic agent haloperidol blocked the effect of DA agonists and of ergot alkaloids in both animal models. The possible action of ergot alkaloids as DA agonists is discussed. Ergot alkaloids Audiogenic seizures Dopamine agonists Circling behaviour 1. Introduction gic synapses, in two rodent pharmacological models. The first model studied is 'audiogen- The pharmacology of the ergot alkaloids is ic' seizures in genetically susceptible mice. complex and not well understood. Peripheral- The severity of the seizure responses to audi- ly, they act on smooth muscle as 5-hydroxy- tory stimulation can be modified by a variety tryptamine (5-HT) antagonists (Goodman and of drugs believed to act on monoaminergic Gilman, 1971) and as a-adrenergic blockers transmission in the brain (Lehmann, 1970).
    [Show full text]